Anti-CD20/ MS4A1/ B1 monoclonal antibody

Anti-CD20/ MS4A1/ B1 antibody for FACS & in-vivo assay

Target products collectionGo to CD20/MS4A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T73215-Ab-1/ GM-Tg-hg-T73215-Ab-2Anti-Human CD20/MS4A1 monoclonal antibodyHuman
GM-Tg-rg-T73215-Ab-1/ GM-Tg-rg-T73215-Ab-2Anti-Rat CD20/MS4A1 monoclonal antibodyRat
GM-Tg-mg-T73215-Ab-1/ GM-Tg-mg-T73215-Ab-2Anti-Mouse CD20/MS4A1 monoclonal antibodyMouse
GM-Tg-cynog-T73215-Ab-1/ GM-Tg-cynog-T73215-Ab-2Anti-Cynomolgus/ Rhesus macaque CD20/MS4A1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T73215-Ab-1/ GM-Tg-felg-T73215-Ab-2Anti-Feline CD20/MS4A1 monoclonal antibodyFeline
GM-Tg-cang-T73215-Ab-1/ GM-Tg-cang-T73215-Ab-2Anti-Canine CD20/MS4A1 monoclonal antibodyCanine
GM-Tg-bovg-T73215-Ab-1/ GM-Tg-bovg-T73215-Ab-2Anti-Bovine CD20/MS4A1 monoclonal antibodyBovine
GM-Tg-equg-T73215-Ab-1/ GM-Tg-equg-T73215-Ab-2Anti-Equine CD20/MS4A1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T73215-Ab-1/ GM-Tg-hg-T73215-Ab-2; GM-Tg-rg-T73215-Ab-1/ GM-Tg-rg-T73215-Ab-2;
GM-Tg-mg-T73215-Ab-1/ GM-Tg-mg-T73215-Ab-2; GM-Tg-cynog-T73215-Ab-1/ GM-Tg-cynog-T73215-Ab-2;
GM-Tg-felg-T73215-Ab-1/ GM-Tg-felg-T73215-Ab-2; GM-Tg-cang-T73215-Ab-1/ GM-Tg-cang-T73215-Ab-2;
GM-Tg-bovg-T73215-Ab-1/ GM-Tg-bovg-T73215-Ab-2; GM-Tg-equg-T73215-Ab-1/ GM-Tg-equg-T73215-Ab-2
Products NameAnti-CD20/MS4A1 monoclonal antibody
Formatmab
Target NameCD20
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD20 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-356Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-385Pre-Made Obinutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-INN-859Pre-Made Ibritumomab Tiuxetan Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-192Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-149Pre-Made Divozilimab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-391Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-387Pre-Made Ocaratuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-248Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody
    BiosimilarGMP-Bios-ab-446Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-617Pre-Made Veltuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-651Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-INN-843Pre-Made Eramkafusp Alfa Biosimilar, Fusion Protein targeting MS4A1/CD20 fused with human IFNA2 (interferon alpha 2) via a peptidyl linker: Recombinant therapeutic protein targeting B1/Bp35/CVID5/FMC7/LEU-16/S7
    BiosimilarGMP-Bios-ab-392Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-189Pre-Made Epcoritamab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-389Pre-Made Ocrelizumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-013Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-075Pre-Made Blontuvetmab biosimilar, Canine Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-INN-1012Pre-Made Technetium (99Mtc) Nofetumomab Merpentan Biosimilar, Radiolabelled Antibody: Anti-MS4A1/CD20 therapeutic antibody
    BiosimilarGMP-Bios-INN-1028Pre-Made Tositumomab Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-598Pre-Made Ublituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-485Pre-Made Ripertamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-ab-487Pre-Made Rituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    BiosimilarGMP-Bios-INN-838Pre-Made Epitumomab Biosimilar, Whole Mab, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species CD20/ MS4A1/ B1 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP000581human MS4A1 Lentivirus particle
    ORF Viral VectorpGMLP000581human MS4A1 Lentivirus plasmid
    ORF Viral VectorpGMLPm000551mouse Ms4a1 Lentivirus plasmid
    ORF Viral VectorvGMLPm000551mouse Ms4a1 Lentivirus particle


    Target information

    Target IDGM-T73215
    Target NameCD20
    Gene ID931,12482,309217,696843,494216,505653,100059000
    Gene Symbol and SynonymsB1,Bp35,CD20,CVID5,FMC7,LEU-16,Ly-44,MS4A1,Ms4a2,S7
    Uniprot AccessionP11836
    Uniprot Entry NameCD20_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000156738
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: CD20, gene name: MS4A1, also named as B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.